Mablink presents at the digital 9th Antibody Industrial Symposium (June 22-25, 2021) Our Chief Scientific Officer, Dr Warren Viricel, is giving a presentation at the 9th virtual Antibody Industrial Symposium …
Mablink’s R&D team authored a scientific article published today (March 9) in the journal “Pharmaceuticals”. The paper “Exatecan Antibody Drug Conjugates based on a hydrophilic polysarcosine Drug-Linker platform” characterizes a …
Dr. Warren Viricel, our company’s Chief Scientific Officer, is invited to present Mablink’s PSARlink™ drug-linker technology at the 12th annual PEGS Europe Virtual summit (Lisbon, PT) on Tuesday, November 10, …
Mablink’s Chief Scientific Officer Warren Viricel presents preclinical data of our drug-linker ADC platform based on the topoisomerase I inhibitor Exatecan vs. HER-2 ADC gold standard Enhertu® in a mouse …
Mablink will present preclinical data of our drug-linker ADC platform based on a topoisomerase I inhibitor vs. gold standard Enhertu in a mouse model of gastric cancer.
Mablink Bioscience will present the latest technological advances of its ADC platform for highly-loaded & highly hydrophilic ADCs
Mablink Bioscience is looking forward to the 10th edition of the World ADC congress in London, Europe’s longest standing and most comprehensive forum in the ADC field.
A new peer-reviewed scientific publication introducing our ADC drug-linker platform is now available online. Abstract Antibody-drug conjugates (ADCs) convey highly potent anticancer drugs to antigen-expressing tumor cells, thereby sparing healthy …
Our new publication is now available online. Abstract: We report the on-resin synthesis of monodisperse (i.e. discrete) polysarcosine compounds and their uses as an hydrophobicity masking entity for the construction of …
